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Abstract   
 
 
 In late 2017, Wake Forest Baptist Medical Center (WFBMC) created a Clinical 
Trials Task Force to identify ways of increasing their volume of industry-sponsored 
clinical trials. Increasing the number of industry-sponsored clinical trials provides many 
benefits, including: (1) offering more cutting-edge treatment options to its patients, (2) 
growing its research portfolio, (3) expanding the reach of its research across the entire 
WFBMC network, and (4) providing additional opportunities for revenue. The author is a 
member of this task force and capitalized on the opportunity to use this capstone project 
to help generate information and ideas that were presented to WFMBC leadership in 
March of 2018.   
 In order for WFBMC to build capacity to increase its volume of clinical trials, 
workflows must be improved in order to have a research infrastructure capable of 
facilitating clinical trial agreements (CTAs) in a timely manner. For this capstone project, 
the author examined a new improvement initiative, the 60-Day Challenge, and conducted 
a literature search to determine what other institutions consider best practices in this area.  
The author also conducted interviews with senior leadership to identify potential research 
infrastructure improvement strategies that could be implemented at WFBMC.  
 The research done for this capstone project led the author to make ten 
recommendations from the findings. These recommendations included continuing the 60-
Day Challenge to allow for parallel submission and review of the budget, contract, and 
regulatory documents; incorporating previously approved contract language and master 
agreements whenever possible to help facilitate faster contract negotiations; and creating 
iii 
a focused pool of dedicated CTA processing staff. These recommendations can help 
WFBMC become more efficient at processing CTAs and become more attractive to 
sponsors, which will promote and support an increase in clinical trials.  
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Chapter 1. Introduction 
 
 
 The aim of this capstone project was to examine the research administrative 
infrastructure at WFBMC and provide recommendations on process improvements to 
support an increase in industry-sponsored clinical trials conducted at WFBMC. Data from 
a survey administered by the Clinical and Translational Science Institute (CTSI) in May 
of 2017 was evaluated to support the need for better workflows. This survey was 
administered to all faculty and staff across the research enterprise and assessed the 
overall effectiveness and satisfaction with the Office of Sponsored Programs (OSP) Pre-
Award, Post-Award, and Contracts Divisions.  
 This capstone project explored an initiative already underway at WFBMC, the 60-
Day Challenge, to see how effective it has been at improving operational efficiencies and 
decreasing the amount of time it takes to execute an industry-sponsored CTA. This 
capstone project also examined current literature related to increasing efficiencies when 
working with industry-sponsored clinical research. It also examined infrastructure needs, 
industry-sponsored master CTAs, and how this information can be utilized at WFBMC. 
Interviews were also conducted with senior leadership in the CTSI to provide insight, 
assess the current environment, and discuss opportunities to optimize workflows in over 
thirty academic departments, centers, and institutes, as well as within central research 
administrative offices.  
1.1 Background 
WFBMC is an academic medical center (AMC) located in Winston Salem, North 
Carolina. It houses the CTSI, partially supported by a Clinical and Translational Science 
2 
Award funded by the National Center for Advancing Translational Sciences. The CTSI 
provides a unified research support mechanism and includes the central research 
infrastructure responsible for the initiation and ongoing review of clinical trials. This 
includes the following three primary offices as outlined in Table 1: Office of Sponsored 
Programs, Office of Clinical Research, and Institutional Review Board.  
Table 1. CTSI offices, their function, and electronic system used 
Office Primary function Electronic system used 
Office of Sponsored 
Programs (OSP) 
Manage all pre-and post-award functions, 




Office of Clinical 
Research (OCR) 
Builds study calendars and budgets in 
WISER to manage study billing; Medicare 
Coverage Analysis; offers resources for 
study coordination, data and regulatory 








Board for the 
Protection of Human 
Subjects (IRB) 
Manages the review and approval of all 
human subjects research  
Huron’s Research 
Suite - an electronic 
IRB (eIRB) 
 
These offices collaborate with over 1,200 faculty and staff who participate in 
research activities. In fiscal year 2017,1 WFBMC received over $205 million in 
sponsored research funding with $10 million coming from industry–sponsored clinical 
research.  
In the fall of 2017, WFBMC leadership created a Clinical Trials Task Force to 
develop strategies to increase clinical trial funding across the medical center, with an 
emphasis on industry-sponsored funding. According to WFBMC’s Chief Science Officer 
                                                          
 1. Academic Fiscal Year 2017 is July 1, 2016 through June 30, 2017. 
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and Senior Associate Dean for Research, “WFBMC is focusing on increasing industry-
sponsored clinical trials as they offer benefits in these four areas:  
1.  Patient Perspective – Clinical trials provide patients with access to cutting-edge 
treatments and care. They allow patients to play a more active role in their care 
and help them understand more about their disease or condition.  
2.  Research Perspective – Industry-sponsored clinical trials address different 
questions than federally sponsored studies, so they help expand the range of 
WFBMC’s research portfolio.  
3.  Clinician Perspective – Clinician involvement is required for most industry-
sponsored clinical trials so this helps spread research across the entire WFBMC 
network.  
4.  Revenue – Since WFBMC is an AMC, it seeks to expand its funding portfolio and 
industry-sponsored clinical trials help bring diversification to its income 
statements.  In addition, industry is considered the best third party payer for 
clinical ancillary services.”2  
 In order to facilitate an increase in clinical trials, the research infrastructure at 
WFBMC needs to be able to build additional capacity to support growth in this key area.  
This capstone project focused on optimizing workflows and staffing recommendations to 
improve the industry-sponsored CTA process.  
                                                          
 2. Gregory Burke, “ Clinical Trial Task Force Charge” (presentation, WFBMC, Winston Salem, 
December 18, 2017). 
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1.2 Statement of the Problem and Needs Assessment 
 In May 2017, the CTSI administered an OSP Programs Assessment Survey (see 
Appendix 1 for complete survey). This survey was created and administered through 
Research Electronic Data Capture (REDCap), a web-based application used for building 
and managing online surveys and databases and was sent to 1,245 faculty and staff. 545 
responses were received with an overall response rate of forty-four percent (281 
responses from staff, 241 from faculty, and twenty-three from OSP staff). The 
comprehensive survey covered a number of topics, including: proposal review and 
submission, InfoEd (WFBMC’s electronic research administration system used to submit 
grants and contracts), contract negotiation, sub-award negotiation, account setup, award 
management, effort reporting, award closeout, customer service, and overall 
effectiveness. For the purposes of this capstone project, the author focused on proposal 
review and submission, contract negotiation, customer service, and effectiveness.   
 As shown in Table 2, OSP is effective at facilitating proposals, mainly federally 
funded grants, but improvement is needed when it comes to facilitating industry-
sponsored contracts and CTAs. OSP had a sixty-three percent positive score where 
faculty and staff felt OSP is very effective or effective at facilitating the overall proposal 
review, approval, and submission of grants while only ten percent surveyed felt OSP is 
ineffective or very ineffective. When compared to how effective OSP was at finalizing 
industry research contracts in terms of speed and timeliness of execution, the 
positive/effectiveness score dropped to thirty percent, while the negative/ineffective score 
rose to thirty-seven percent. This data shows that faculty and staff feel that OSP can be 
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more effective at reducing the turnaround time for executing industry contracts, have 
better customer service, and do more to reduce administrative burden. Administrative 
burden can include any barriers that exist including the paperwork needed to initiate the 
negotiations of a CTA as well as compliance and regulatory approvals. 
Table 2. OSP assessment survey results  
 
 WFBMC is not alone in thinking improvements can be made in order to increase 
efficiencies regarding the start-up of industry-sponsored projects. WFBMC metrics 
indicate the time from receipt of industry-sponsored regulatory documents to trial 
Survey Question Positive* Neutral* Negative*
Indicate how effective OSP is at facilitating the overall 
proposal review, approval, and submission process. 63% 27% 10%
In terms of minimizing the administrative burden on 
investigators, how well does the overall proposal review, 
approval, and submission process meet expectations? 20% 56% 24%
Indicate how effective OSP is at finalizing industry research 
contracts in terms of speed/timeliness of execution. 30% 33% 37%
Indicate how effective OSP is at communicating the status of 
industry contracts. 34% 32% 34%
The individuals within the OSP Contracts Office have the 
right level of expertise and knowledge to perform their job 
duties and answer my questions. 56% 30% 14%
The OSP Contracts Office team members display a strong 
customer service attitude to my email and/or phone inquiries. 53% 28% 19%
Please rate your overall satisfaction with the response of the 
OSP Contracts Office to your questions, emails and/or phone 
inquiries. 50% 27% 23%
*Positive includes the following categories: Strongly Agree/Agree, Very Effective/Effective, 
Significantly Above Expectations/Above Expectations, Very Satisfied/Satisfied, Very User-
Friendly/User-Friendly
*Neutral includes the following categories: Neither Agree nor Disagree, Somewhat Effective, Meets 
Expectations, Neither Satisfied nor Dissatisfied, Somewhat User-Friendly
*Negative incudes the following categories: Disagree/Strongly Disagree, Ineffective/Very Ineffective, 
Below Expectations/Significantly Below Expectations, Dissatisfied/Very Dissatisfied, Not User-
Friendly/Not At All User-Friendly
*Responses of "Not Applicable" or "I don't know" were not included in the percentages above
6 
activation was a median of 150 days.3 When compared to other institutions, Vanderbilt-
Ingram Cancer Center had a median of 171 days,4 and median times from submission to 
opening a trial were 163 days for Washington University School of Medicine and 112.5 
days for University of Torino.5 These institutions also questioned what could be done to 
improve their internal processes in order to reduce the number of days it takes to initiate 
industry-sponsored clinical trials. This was a driving force behind a new initiative 
implemented in December of 2017 at WFBMC called the 60-Day Challenge. The 60-Day 
Challenge is a partnership between departments and the CTSI in which all parties commit 
to accelerating the submission and review of IRB applications, as well as budget and 
contract documents to help expedite the contracting and study start-up process. 
Preliminary data from the Challenge are reviewed and discussed as part of this capstone 
project.  
1.3 Research Questions 
 This capstone project was designed to explore what can be done to improve the 
industry contracting process at the institutional level. The author acknowledges the 
industry sponsor and/or their contract research organization (CRO) plays a role in this 
process as well, but the author focused on what can be done internally to make process 
                                                          
 3. Chris O’Byrne, interview with author, Winston Salem, December 8, 2017. 
 4. David Dilts and Alan Sandler, “Invisible Barriers to Clinical Trials: The Impact of Structural, 
Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” Journal of Clinical 
Oncology 24, no. 28 (October 2006): 4550, accessed March 20, 2018, http://dx.doi.org/10 
.1200/JCO.2005.05.0104.  
 5. Andrea Wang-Gillam et al., “Time to Activate Lung Cancer Clinical Trials and Patient 
Enrollment: A Representative Comparison Study Between Two Academic Centers Across the Atlantic,” 
Journal of Clinical Oncology 28, no. 24 (August 2010): 3804, accessed March 20, 2018, http://dx.doi 
.org/10.1200/JCO.2010.28.1824.  
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improvements. The following research questions were considered for this capstone 
project: 
1. What improvements can be made within OSP to better facilitate CTAs?  
2. What improvements can be made within departments to better facilitate CTAs?  
3. What are other institutions doing to improve the industry contracting process?  
4. Are the goals of the 60-Day Challenge being met and should it continue?  
1.4 Research Objective 
 The objective of this capstone project was to provide recommendations to the 
CTSI leadership on process improvements to better facilitate CTAs. This will in turn help 
build capacity that will allow the institution to better position itself to grow in the number 











Chapter 2. Literature Review 
 
 
 Trying to reduce research administrative burden is not just an issue at WFBMC, it 
is a systemic problem as shown in the 2012 Federal Demonstration Partnership Survey. 
This survey showed principal investigators (PIs) spend, on average, forty-two percent of 
their time on administrative tasks related to conducting federally funded research.6 While 
this survey focused on the administrative burden placed on university researchers who 
have been awarded federal grants, many of the same burdens exist for university 
researchers working on industry-sponsored research.   
 In order to assess best practices in facilitating industry-sponsored clinical trials at 
other research institutions, a literature search was conducted to evaluate best practices at 
other institutions and determine what could be implemented at WFMBC to help address 
the first three research questions:   
1. What improvements can be made within OSP to better facilitate CTAs?  
2. What improvements can be made within departments to better facilitate CTAs?  
3. What are other institutions doing to improve the industry contracting process?  
This chapter discusses literature related to the following areas: (a) increasing efficiencies 
in executing CTAs, (b) infrastructure needs to support an increase in clinical trials, and 
(c) the use of master CTAs. 
                                                          
 6. Sandra Schneider, Kirsten Ness, Sara Rockwell, Kelly Shaver, Randy Brutkiewicz, “2012 
Faculty Workload Survey Research Report,” Federal Demonstration Partnership (FDP), April 2014, 
assessed January 30, 2018, http://sites.nationalacademies.org/cs/groups/pgasite/documents/ webpage/pga 
_087667.pdf.   
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2.1 Increasing Efficiencies in Executing Clinical Trial Agreements 
 There are a number of factors that can delay the start-up of clinical trials including 
contract negotiations, budget negotiations, and the IRB review and approval, with delays 
in contract negotiations being the most common. Rijswijk-Trompert suggests these 
delays are often tied to lack of clear processes, training, and communication of the staff 
who process CTAs.7 This article suggests that, as often as possible, contracts offices 
should have well written contract templates that include language that has been 
previously approved.8 Another recommendation was to set communication guidelines 
during training as communication is often seen as a barrier during contract negotiations.9  
 There are also processes unrelated to contract negotiations that can ultimately 
delay executing an industry contract, including IRB reviews, budget negotiations, finance 
office approval, and management of conflicts of interest. Baer et al. suggest that the 
establishment of processes that include a parallel review of the items listed above can 
reduce the time it takes to activate a clinical trial.10 Baer et al. also suggest “Establishing 
a culture in which all members of the research team understand the importance of 
conducting their role in an efficient manner is imperative.”11 When all parties involved 
know their role, this can prevent avoidable mistakes and misses, and in turn reduce 
contract negotiation turnaround time. Internal deadlines should also be used to improve 
                                                          
 7. Myrthe Rijswijk-Trompert, “Clinical Trial Agreement Negotiations,” Applied Clinical Trials 
21, no. 6 (June 2012): accessed January 19, 2018, http://www.appliedclinicaltrialsonline.com/clinical-trial  
-agreement-negotiations. 
 8. Ibid.  
 9. Ibid.  
 10. Allison Baer et al., “Clinical Research Site Infrastructure and Efficiency,” Journal of 
Oncology Practice 6, no. 5 (September 2010): 251, accessed February 15, 2018, 
http://dx.doi.org/10.1200/JOP .000109. 
 11. Ibid.  
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efficiency for the various stages of review and approval and reminders should be sent 
when these deadlines are due and when they are missed. One example is requiring a 
response to IRB concerns within seventy-two hours, which has been found to reduce the 
number of days it takes to receive IRB approval.12 
 In order to conserve staff time and resources for clinical trials that are most likely 
to be successful, it may be helpful to assess the feasibility of protocols prior to 
proceeding with IRB submission, contract review, and budget approval. Feasibility 
committee reviews can help determine whether or not a clinical trial should be 
implemented at the institution. These reviews can include evaluating the patient 
population to ensure the site has enough patients that can be enrolled in the trial and that 
the site has the capabilities for any specific imaging or specimen processing 
requirements.13 Baer et al. recommend that the feasibility committee should be made 
aware of how many sites are already up and running and how many patients are available 
to enroll overall.14 This will help ensure there will be enough time for the site to go 
through the contracting and startup process and still have time to enroll enough patients. 
If a clinical trial cannot enroll enough patients, it may result in not only a loss of potential 
revenue, but it can cost the institution thousands of dollars.15 
 
                                                          
 12. Baer et al., “Clinical Research Site Infrastructure and Efficiency,” 251. 
 13. Ibid. 
 14. Ibid. 
 15. Allison Baer, Cary Cohen, Dee Anna Smith, Robin Zon, “Implementing Clinical Trials: A 
Review of the Attributes of Exemplary Clinical Trial Sites,” Journal of Oncology Practice 6, no. 6 
(November 2010): 329, accessed February 18, 2018, http://dx.doi.org/10.1200/jop.2010.000156. 
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2.2 Infrastructure Needs to Support an Increase in Clinical Trials  
 In addition to exploring the use of a feasibility committee to review protocols 
prior to implementation, it is important that all faculty and staff participating in clinical 
trials are properly trained in Good Clinical Practice (GCP) so they better understand the 
rules and regulations associated with conducting human subjects research.16 Additional 
education and training is also recommended and is available through organizations such 
as the National Council of University Research Administrators (NCURA), Society of 
Clinical Research Associates (SOCRA), and the Association of Clinical Research 
Professionals (ACRP).  
 Zon et al. recommends that an institution strive to maintain a high level of quality 
in its research programs.17 They believe one way to achieve this is by implementing a 
quality assurance program to help identify strengths and weaknesses within any number 
of research programs. The authors suggest research programs utilize standard operating 
procedures (SOPs) and require routine review of these procedures.18  This article also 
suggests that both physicians and non-physicians should be engaged in research across all 
disciplines as this will allow the site the opportunity to participate in more clinical trials 
that will in turn offer more diverse options for its patients.19  
  In addition to offering education, training, and requiring the periodic review of 
SOPs, AMCs should also provide a unified research support office that offers 
                                                          
 16. Baer et al., “Implementing Clinical Trials,” 330. 
 17. Robin Zon, Gary Cohen, Dee Anna Smith, Allison Baer, “Part 2: Implementing Clinical 
Trials: A Review of the Attributes of Exemplary Clinical Trial Sites,” Journal of Oncology Practice 7, no.1 
(January 2011): 61, accessed February 18, 2018, http://dx.doi.org/10.1200/jop.2010.000185. 
   18. Ibid.  
 19. Ibid., 62. 
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harmonization of administrative support. The Duke University Office of Clinical 
Research formed in 2012 to help provide support to researchers and staff throughout the 
entire spectrum of conducting research by providing personnel to help reduce the 
administrative burden of investigators and study teams. The unified organizational 
structure at Duke provides personnel support from the following offices: Clinical 
Research Finance, Study Startup, Electronic Health Record Build and Support, Research 
Management Team, Training and Communication, and Outreach and Mentorship. This 
model has shown to increase efficiencies over time by decreasing the time from 
institutional approval to enrolling the first participant, increasing the overall number of 
clinical trials Duke participates in, and increasing the number of patients accrued into 
their studies.20   
2.3 Use of Master Clinical Trial Agreements 
 When seeking to reduce the turnaround time of executing CTAs, institutions 
should use previous negotiated terms as much as possible to avoid recreating language 
already approved by the institution.21 Researchers at the University of California, 
Biomedical Research, Acceleration, Integration, and Development found using a master 
CTA reduced the amount of time it took to finalize terms of a CTA by an average of 
thirty-four days, a forty-seven percent reduction in negotiation time.22 In addition, 
industry sponsors with master CTAs took significantly fewer days to finalize terms with 
                                                          
   20. Denise Snyder et al., “Retooling institutional support infrastructure for clinical research,” 
Contemporary Clinical Trials 48 (May 2016): 139, accessed January 19, 2018, http://dx.doi.org/10 
.1016/j.cct.2016.04.010.  
 21. Rijswijk-Trompert. 
 22. Tam Tran et al., “Collaboration in Action: Measuring and Improving Contracting Performance 
in the University of California Contracting Network,” Research Management Review 22, no. 1 (2017): 5, 
accessed January 19, 2018, https://files.eric.ed.gov/fulltext/EJ1134105.pdf.  
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their sites: forty-six days compared to seventy-six days for those who did not use master 
agreements.23 
2.4. Methods Used in Literature Review for Best Practices 
 In order to help reduce the administrative burden of conducting industry-
sponsored research, the author sought to review literature on how to increase efficiencies 
in executing CTAs, infrastructure needs to support an increase in clinical trials, and use 
of master CTAs. The goal of this literature review was to evaluate what other institutions 
are doing as best practices to provide recommendations to help WFMBC reduce 
administrative burdens related to industry-sponsored research.   
 The author used Google as the search engine and PubMed to find manuscripts and 
conducted searches using the following keywords:  
• Research administrative infrastructure at a university 
• Best practices within office of sponsored programs 
• Use of master agreements for industry-sponsored research 
• Attributes of exemplary clinical trial sites 
• Increase efficiencies in executing clinical trial agreements  
 The articles chosen for the literature review section were selected based on their 
relevance to the research question “What are other institutions doing to improve the 
industry contracting process?”. These articles also helped the author understand what is 
being implemented at other institutions in order to provide recommendations on process 
improvements within OSP and departments to better facilitate industry research contracts.     
 
                                                          
23. Tran et al., 5.  
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Chapter 3. Project Description 
 
 
 This chapter provides a description of the capstone project and discusses why the 
author chose to write about increasing efficiencies in order to reduce the time it takes to 
start an industry-sponsored clinical trial. The aim of this project was to examine the 
research administrative infrastructure at WFBMC and provide recommendations on 
process improvements to support an increase in clinical trials conducted at WFBMC. The 
author, who leads a large study team at the department-level, is passionate about this 
topic and regularly interacts with the CTSI to facilitate sponsored projects. This capstone 
project came at the right time as the author was selected to participate on the Clinical 
Trials Task Force given her experience at WFBMC, as well as her increased skills and 
knowledge as a result of participating in the Johns Hopkins Master of Research 
Administration program.  
 The task force first implemented the 60-Day Challenge as a means of reducing the 
time it takes to facilitate a CTA. In addition, the task force wanted to see what else could 
be done to increase its volume of clinical trials. Since the author had first-hand 
knowledge of many of the inefficiencies and administrative burdens that prevent some 
researchers from participating in clinical trials, she wanted to explore what else could be 
done to help build a research infrastructure capable of handling an increase in industry-
sponsored projects. As a result, the author chose to examine data from the 60-Day 
Challenge, conduct a literature review to explore best practices at other institutions, and 
interview key leaders within the CTSI. This information contributed to presentations on 
15 
recommended best practices for WFBMC leadership to consider, and was the basis for 











































Chapter 4. Methodology 
 
 
 This chapter discusses the methods used to gather data in order to provide 
recommendations on how workflows can be improved to build capacity for increasing 
clinical trials at WFBMC.  
4.1 The 60-Day Challenge  
 Time is of the essence as sponsors and CROs are trying to finalize clinical sites to 
conduct clinical trials as quickly as possible and sites want the opportunity to enroll as 
many patients as possible to make sure the study will be fiscally feasible. As noted on the 
results of the OSP Assessment Survey, the majority of WFBMC faculty and staff were 
either neutral or dissatisfied with how well the institution minimalizes the administrative 
burden associated with the submission, review, and approvals of sponsored research.  
 The contracts office within OSP at WFBMC is tasked with negotiating contract 
terms and conditions of CTAs with the sponsor or CRO. Study teams have to work with 
both groups and there are numerous steps in the workflows that can impede the efficiency 
of the process. The current process at WFBMC is inefficient and causes industry-
sponsored clinical trials to take a median of 150 calendar days from receipt of industry-
sponsored regulatory documents to trial activation.24  In an effort to improve the 
turnaround time of finalizing CTAs, the CTSI leadership implemented a new program in 
December 2017 called the 60-Day Challenge.  
                                                          
 24. Chris O’Byrne, interview with author, Winston Salem, December 8, 2017. 
17 
 There are two phases of the 60-Day Challenge. Phase I of the Challenge has study 
teams perform sequential targeted submissions and conducts parallel reviews in place of a 
process that has traditionally been haphazard with sequential reviews which caused 
delays at multiple points in the process as shown on top in Figure 1.25 This workflow 
includes submitting the project to the IRB, submitting the budget to the OCR for review 
and approval through WISER, and submitting the draft contract to OSP through InfoEd, 
all within two weeks of each other so the reviews occur concurrently, as shown at the 
bottom of Figure 1.  
Figure 1. Pre and Post 60-Day Challenge workflows  
                                                          
 25. Figure 1 adapted from Selvin Ohene, Director of the Office of Clinical Research, Unpublished 
60-Day Challenge presentation slide, Winston Salem, 2017.  
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 Phase II of the Challenge is to have all central office internal reviews and 
approvals for industry-sponsored clinical trials in sixty calendar days or less, which, if 
successful, will represent a sixty percent decrease in initiation time. This initiative 
requires a close partnership between WFBMC PIs, study teams, the OSP, the OCR, and 
the IRB to eliminate redundancy and improve workflows for trial initiation. The 
Challenge grew out of concern by CTSI leadership that clinical trials were being delayed, 
with consequences of fewer trials being initiated at WFBMC, patients not being offered 
potentially valuable treatments, and missed revenue opportunities. The Challenge aims to 
reduce the number of days to study activation by removing duplicative processes and 
creating a model of shared responsibility between departments and the central office.  
 Communication with the sponsor or CRO is also critical so that they are aware of 
how fast WFBMC can process the CTA. This quick response from WFBMC is designed 
to encourage more timely responses from the sponsor or CRO and to let the sponsors or 
CRO know that WFBMC is ready to enroll participants in the study. Because the 
Challenge requires a commitment by the department and allocation of additional 
resources to ensure timely submissions and responses, the Challenge is currently 
considered optional. Currently six distinct academic units have enrolled in the Challenge, 
including Neurology, Gerontology, Cardiovascular Medicine, Pulmonary, 
Anesthesiology, and Obstetrics and Gynecology.26 This capstone project reviewed the 
preliminary data from this initiative to see if process improvements already in place are 
working in order to see if the Challenge should be expanded across the institution. Data 
                                                          
  26. Departments participating as of April 13, 2018. 
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was examined to see if study teams achieved the goal of submitting all required 
documents within two weeks and to see if the time from receipt of industry-sponsored 
documents to trial activation had decreased.  
4.2 Interviews with Senior Leadership 
 Data from faculty and staff at WFBMC showed a need for reducing 
administrative burden and increasing OSP efficiencies.27 The author wanted to meet with 
CTSI leadership to get their perspective on how these issues can be addressed. In 
selecting whom to meet with, the author felt it was important to interview leaders in each 
of the key units involved in facilitating CTAs. This was done in order to get a better 
understanding of hindrances that could preclude process improvements. The units 
interviewed included overall research administration, the OSP, the OCR, and the IRB, all 
of which are located within the CTSI.  
 The author first met with the Vice President and Associate Dean for Research 
Administration and Operations.28 This position is responsible for the oversight of all 
research infrastructure programs associated with the CTSI and includes Research 
Administration (where OSP is housed), Animal Research, Clinical Research (where IRB 
and OCR are housed), Research Education, Community Engagement, Biomedical 
Informatics, Technology, and Center and Core Administration. The interview started with 
the author presenting her capstone project idea to receive feedback on information that 
could be helpful to the institution and to the Clinical Trials Task Force. One concern the 
author had was the possibility OSP is inadequately staffed, but was assured staffing levels 
                                                          
 27. Data from the Office of Sponsored Programs Assessment Survey shown on page 5. 
 28. Chris O’Byrne, interview by author, Winston Salem, December 8, 2017.  
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in the contracts office and the OCR were not the issue. Huron Consulting Group 
conducted a review of OSP in February of 2017, which showed that, when compared to 
peer institutions, benchmarks indicate that these areas within OSP are adequately staffed. 
This suggests that operational inefficiencies were driving the delays in clinical trial 
activation. This meeting was important for the author to obtain buy-in for the project and 
to get permission to access data from the OSP Assessment Survey and the 60-Day 
Challenge. 
 Since processing CTAs occurs mainly within the contracts office of the OSP, the 
author also met with the Interim Director of OSP and Associate Director of Contracts.29 
This person leads a team of eight staff and this team ensures CTAs, confidentiality 
agreements and material transfer agreements are negotiated in accordance with 
institutional standards and federal requirements.  Since this person knows first-hand about 
the operational workflows involved in negotiating industry CTAs, the author conducted a 
semi-structured interview to gain insight on the current process improvement initiative, 
the 60-Day Challenge, and its progress to date. The author also asked questions about the 
following: 
• results from the OSP assessment survey 
• known best practices we could implement  
• plan to increase the number of master agreements with industry sponsors 
• ideas on process improvements in addition to the Challenge 
The information gathered during this interview helped formulate the process 
improvement suggestions presented in the results and recommendations chapters.  
                                                          
 29. Robyn Gore, interview by author, Winston Salem, February 16, 2018. 
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 Much of the work done when initiating industry-sponsored clinical trials, outside 
of negotiating CTAs, is completed within the OCR. This office is led by the Director of 
the OCR. He serves as a resource for clinical trials and study management, as well as 
assisting with reviewing clinical trial budgets, entering budgets into WISER, promoting 
active participant management, and promoting accurate research billing. The author met 
with the Director of the OCR30 and asked him questions related to the following:  
• insight from previous institutions where he worked that would be valuable to 
implement or any other known best practices 
• thoughts on an expanded OCR that could provide more services and support 
• need for a Feasibility Committee 
• what else can be done to increase the amount of clinical trials at WFBMC 
The information discussed during this interview was used to formulate the process 
improvement suggestions presented in the results and recommendations chapters.  
 The WFBMC IRB is responsible for reviewing and approving all human subjects 
research conducted at the institution. Traditionally, WFBMC prefers to be the IRB of 
record for industry-sponsored clinical trials and has been reluctant to always allow the 
use of industry’s selection of a central IRB, such as Copernicus, Schulman, or Western, 
as it takes some of the oversight away from the local WFBMC IRB. The author met with 
the Director of the IRB31 and asked if the WFBMC IRB would start accepting the use of  
central IRBs more for industry-sponsored research since the National Institute of Health 
(NIH) is now requiring the use of single IRBs for multi-center human subjects research 
                                                          
 30. Selvin Ohene, interview by author, Winston Salem, February 28, 2018. 
 31. Brian Moore, interview by author, Winston Salem, March 23, 2018.  
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protocols funded by the NIH.32  The use of a central IRB is often preferred by sponsors or 
CROs as it helps expedite study-start up as it removes this process from the research site. 
























                                                          
 32. “Final NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research,” 
NIH Policy Notice Number: NOT-OD-16-094, accessed March 24, 2018, https://grants.nih.gov 
/grants/guide/notice-files/NOT-OD-16-094.html. 
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Chapter 5. Results  
 
 
 This chapter summarizes the preliminary data from the 60-Day Challenge, as well 
as the information learned from conducting literature reviews and interviews with senior 
leadership.      
5.1 The 60-Day Challenge 
 The 60-Day Challenge was implemented in December 2017 with the goal of 
having all central office internal reviews and approvals for industry-sponsored clinical 
trials completed in sixty calendar days or less from the receipt of all three required 
components. This includes: (1) review and approval of the contract information within 
InfoEd, (2) review of the budget information, Medicare coverage analysis, and calendar 
build to set up the budget and research billing within WISER, and (3) the regulatory 
review within the eIRB.  Since December, six units have opted in to the challenge 
including Neurology, Gerontology, Cardiovascular Medicine, Pulmonary, 
Anesthesiology, and Obstetrics and Gynecology.  
 To date,33 a total of eleven projects from the participating units have begun phase 
I of the Challenge by submitting at least one component into eIRB, WISER, or InfoEd. 
The goal is to have all three submissions done in parallel.34 Only one of these projects 
was been able to submit all three components within the recommended two weeks, with 
the complete submissions ranging from thirty-seven days to fifty-seven days. Four 
projects have submitted all three components and entered phase II which starts the 
                                                          
 33. As of April 12, 2018. 
 34. Defined as all three components submitted within two weeks of each other. 
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official count of the number of days it takes to review and approve the project. Of these 
four projects, projects 1 and 2 have received full approval within sixty days and projects 
3 and 4 are on track to receive full approval within sixty days (see Table 3). 
  
 Of the seven remaining projects that do not have all three components submitted, 
notes from the system used to track this information indicate that the holdups are with the 
sponsor and the study team.35 Once the study teams are able to submit the remaining 
components, the clock will start allowing these seven projects to begin phase II of the 60-
Day Challenge.    
5.2 Literature Review for Best Practices 
 A literature review was done to help provide insight on what other institutions are 
doing to see what information could help increase efficiencies in getting clinical trials 
initiated faster to help address research questions 1-3. A reoccurring theme throughout 
the literature review recommends that institutions use contract templates and previously 
                                                          
   35. Results emailed from Robyn Gore included dates and notes in an excel file.  
Table 3. 60-Day Challenge data
Projects receiving full approval
Project Submission 
date
Approval date Days to 
completion
1 1/23/2018 3/19/2018 55








3 3/4/2018 5/3/2018 42
4 3/13/2018 5/12/2018 33
Projects pending full approval
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negotiated language as much as possible,36 including the use of master agreements37 as 
this can significantly reduce the time it takes to negotiate a CTA, thereby allowing the 
clinical trial to start-up quickly. This information is helpful as developing master 
agreements is a considerable amount of work, but data from Tran et al. show master 
agreements can be an excellent way of reducing the time it takes to finalize a CTA.38  
 The literature also suggests establishing processes that include a parallel 
submission and review of all items needed in order to execute an industry contract, 
including IRB reviews, budget negotiations, finance office approval, and management of 
conflicts of interest. This can decrease the time it takes to activate a clinical trial.39 In 
addition, all parties involved should understand their role and be able to clearly define 
their duties as it relates to submitting and reviewing CTA documents.40 Baer et al. also 
suggest having internal deadlines so all parties are aware of when documents or 
responses to concerns are due to avoid delays due to lack of timeliness.41 The goal is to 
prevent avoidable delays so all components of the CTA can be reviewed and approved as 
soon as possible. In addition to everyone knowing their roles, staff should also have the 
proper education, training, and support to conduct their job.42 The information learned 
from these articles suggest best practices that could be implemented at WFBMC to help 
facilitate CTA and reduce the time it takes to receive all necessary approvals.  
                                                          
 36. Rijswijk-Trompert. 
   37. Tran et al., 5. 
 38. Ibid. 
 39. Baer et al., “Site Infrastructure and Efficiency,” 251. 
 40. Ibid. 
 41. Ibid. 
  42. Baer et al., “Implementing Clinical Trials,” 329.  
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 Baer et al. suggest institutions who field a significant amount of clinical trials that 
either never enroll a patient or lose money should create a Feasibility Committee.43 A 
Feasibility Committee would assess all potential clinical trials prior to starting contract 
and budget negotiations and the IRB submission to ensure the project is viable given the 
patient population and the timeframe left to enroll new patients. While creating a 
Feasibility Committee may save resources in the long run, it would also take a lot of 
resources to facilitate and should be further examined to see if the study team can 
evaluate a study’s feasibility without having to involve a committee that may slow down 
the study start-up process.  
 The article from Denise Snyder et al. on the reorganization of Duke University’s 
OCR suggests a unified research support office is beneficial to all involved in research as 
it has been shown to decrease the time it takes to enroll the first patient once a trial has 
been activated, increase the overall number of the clinical trials, and increase the number 
of their patients participating in these trials.44 WFBMC has a unified research support 
office (the CTSI) and while it offers many of the same resources, there may be 
opportunities to expand in order to help accommodate an increase in industry-sponsored 
clinical trials. 
5.3 Interviews with Senior Leadership 
 The author interviewed the following key leaders at WFBMC: the Vice President 
and Associate Dean, Research Administration and Operations; the Interim Director of the 
OSP and Associate Director of Contracts; the Director of the OCR; and the Director of 
                                                          
   43. Baer et al., “Implementing Clinical Trials,” 329.  
   44. Snyder et al., 139. 
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the IRB. These interviews were conducted to seek their buy-in for this project, access 
data, and determine what ideas they may have to optimize the research administrative 
infrastructure at WFBMC. During these interviews, all of the interviewees agreed that 
processes to submit and review documents related to a CTA could be further streamlined 
and a common theme emerged as everyone agreed there are “too many hands in the pot”.     
 One suggestion was made to reorganize duties within the contracts office so those 
who negotiate CTAs with sponsors and CROs focus their time on this function, with 
other duties, such as negotiating confidentiality agreements and material transfer 
agreements, being reassigned to others within the contracts office. CTAs are the most 
critical and if staff were not slowed by other tasks, it might improve the turnaround time 
for contract negotiations. Another suggestion involved those who prepare the 
submissions in WISER, InfoEd, and IRB as outlined in Figure 1. The submission of 
documents and information into these systems is currently the responsibility of 
departmental staff who have numerous other competing tasks associated with conducting 
research. A suggestion was made to take this responsibility out of the department and 
centralize these functions with support from the CTSI. The intent is to promote focused 
attention on these processes with limited distractions.  
 When asked about master agreements, the Associate Director of Contracts 
confirmed the ability to expedite contract negotiations since only an addendum is needed, 
but stated that even if the contract negotiations are complete, the IRB and WISER 
submissions can still hold up the process of activating a clinical trial. This could be 
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eliminated with parallel submissions of these components, as suggested by the 60-Day 
Challenge.  
 When asked about the how WFBMC can increase the number of clinical trials it 
participates in, the Director of the OCR felt the best way was to try and get repeat 
business from the sponsors and CROs with whom WFBMC already has a relationship. 
This would help expedite contracts, as much of the contract language would already be 
negotiated. In order to increase the likelihood of repeat business, he suggested creating a 
quarterly report card that allows sponsors to determine how well WFBMC is meeting 
their needs. This would help identify any problems early and maintain open 
communication between the site and the sponsor, which will allow the sponsor and/or 
CRO to understand the benefits of choosing WFBMC as a site for future trials.  
 The Director of the WFBMC IRB acknowledged that sponsors and CROs of most 
industry-sponsored clinical trials prefer the use of a for-profit central IRB as it helps 
expedite the study start up by preventing duplicative review and approval of the study 
protocol, advertisements, informed consent forms, study documents, etc. WFBMC has 
traditionally been hesitant in allowing the use of a for-profit central IRB and prefers the 
use of its own local IRB to review and approve industry-sponsored projects as it has more 
oversight and control. WFBMC IRB board members feel this is important since these 
projects tend to be clinical trials involving investigational medications or devices and can 
include more risk than other research projects. The Director of the IRB stated the 
WFBMC IRB plans to allow the use of a central IRB, like Copernicus, for more projects 
assuming the central IRB is accredited by the Association for the Accreditation of Human 
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Research Protection Programs and the study team is experienced and knowledgeable in 
managing industry-sponsored clinical trials. This change will allow researchers at 
WFBMC the opportunity to participate in clinical trials they may not have otherwise been 

















Chapter 6. Recommendations and Conclusion 
 
 
 This chapter starts by offering recommendations to WFBMC leadership based on 
the literature review conducted, interviews with senior leadership, survey responses, and 
the preliminary data from the 60-Day Challenge. This chapter ends with a summary of 
the capstone project.  
6.1 Recommendations 
1.  Recommendation: The 60-Day Challenge should continue to allow for parallel 
submission and review.  
 Given the limited data, it is difficult to say if the 60-Day Challenge is sustainable 
due to outside variables, mainly because of delays in sponsor feedback.  However, it 
should continue as there is no harm in having expedited submissions to allow for parallel 
reviews as recommended by Baer et al.45 Ideally, as this initiative moves from its current 
pilot phase, the workflows will become standard practice across the institution so this will 
no longer be considered a “challenge”. 
2.   Recommendation: When working with a repeat industry sponsor, the institution 
should use standardized contract language that has been previously reviewed, 
limiting the administrative and review burden for all parties.   
 Conducting a search of previously negotiated contracts and finding the most 
recent or similar contract from the same sponsor will allow for easy implementation of 
this recommendation. When requesting changes, the contracts office can refer to 
                                                          
  45. Baer et al., “Site Infrastructure and Efficiency,” 251. 
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previously negotiated language in hopes the change is accepted without incident. This 
should help cut down on negotiations and improve turnaround time. 
3.   Recommendation: The institution should create master agreements with its most 
frequent industry sponsors.  
 As shown by Tran et al., master agreements can reduce the time it takes to 
negotiate a CTA by forty-seven percent.46 Since contract negotiations often contribute to 
delays, anything that can be done to decrease CTA negotiation time should be done, 
especially if WFBMC works with the same sponsor for multiple projects. This is likely to 
encourage repeat business from the sponsor.    
4.   Recommendation: All persons involved in clinical research should be required by 
the institution to take a GCP training course. 
 Most sponsors require adherence to the principles of GCP in order to comply with 
Food and Drug Administration regulations regarding the conduct of human subject 
research. In addition, the NIH enacted a new policy where all NIH-funded investigators 
and staff should be trained in GCP.47 Requiring this training will allow WFBMC 
investigators and staff to be compliant with these regulations and will not slow down the 
start-up process if someone has yet to complete this training.  
                                                          
   46. Tran et al., 5. 
   47. “Policy on Good Clinical Practice Training for NIH Awardees Involved in NIH-funded 
Clinical Trials,” NIH Policy Notice Number: NOT-OD-16-148, accessed March 23, 2018, 
https://grants.nih.gov /grants/guide/notice-files/not-od-16-148.html. 
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5.   Recommendation: All persons involved in clinical research should be encouraged 
to join NCURA, SOCRA, ACRP or like organization where they can access 
important information related to their job and gain professional knowledge.  
 Faculty and staff who are members of professional organizations are given 
professional development opportunities that extend beyond those offered at WFBMC. 
These organizations are a great way for researchers and staff to stay abreast of new rules 
and regulations, collaborate, and attend regional and national meetings to gain additional 
knowledge. This is critical when working with federal and industry sponsors and further 
engages individuals to build a solid foundation for WFBMC’s research infrastructure.  
6.   Recommendation: All staff fielding a CTA should have a checklist, including 
required timelines for completion, that lays out each step in the process.  
 Having checklists provides an overview of all items needed to facilitate a CTA 
and can be helpful for new staff or those who do not process CTA frequently. Checklists 
that include timeframes can help staff stay on task and ensure nothing is missed so 
parallel submissions are completed which can help expedite the review and approval of 
all components related to a CTA.  
7.   Recommendation: WFBMC should develop SOPs to help study teams assess the 
feasibility of a new industry-sponsored clinical trial.  
 With a focus on pace and efficiency, SOPs can be used as an alternative to 
feasibility committees, which are often viewed as slow and obstructionist. SOPs will 
determine which studies to expect and outline the resources available within the CTSI, 
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and items to consider such as the budget, patient population, resources needed, and 
availability of the study team. 
8.   Recommendation: Expand services to include more staff who can process new 
CTAs and IRB submissions.  
 Since the institution already has a unified research administrative office (the 
CTSI) and provides many of the same services that Duke’s OCR does, the author 
believes that more staff need to be trained in these areas in order to improve workflows 
and increase productivity. Based on the literature search and interviews with CTSI 
leadership, this could help build capacity for an increase in clinical trial activity. 
Providing additional staff capable of submitting contracts and budgets for review and 
completing IRB submissions will reduce the administrative burden on study teams, 
improving their ability to focus on conducting research. This would aid in parallel review 
and approval of the various components since these staff would not have other competing 
priorities.  
9.   Recommendation: Require that contracts staff that process CTAs should only 
process CTAs. 
 Those who negotiate CTAs will be able to focus on them and not be burdened by  
less urgent transactions like confidentiality agreements and material transfer agreements. 
This allows contracts officers to specialize on specific types of agreements, which is 
likely to help increase efficiencies and decrease the amount of time each agreement takes 
to be finalized.  
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10.  Recommendation: Develop a report card that sponsors can use to provide 
feedback. 
 Having feedback from sponsors would allow WFBMC to track satisfaction with 
its services and support. This feedback could be useful in knowing where improvements 
should be made to improve the quality, time, and efficiency. Addressing any issues that 
may arise can help ensure sponsor satisfaction and may encourage the sponsor or CRO to 
engage WFBMC in future projects.  
6.2 Conclusion  
 Process improvements are needed to build a research administrative infrastructure 
conducive to supporting an increase in CTAs and, in turn, an increase in the volume of 
clinical trials at WFBMC. The goal of this capstone project was to explore what can be 
done to improve the industry contracting process at the institutional level in order to 
streamline processes and provide better support for study teams and offices within the 
CTSI that process the submission, review, and approval of CTAs. Current improvement 
initiatives were examined and while the 60-Day Challenge is still relatively new, the 
streamlined processes and parallel reviews offer study teams who are willing to submit 
all required documents within two weeks of each other the opportunity to expedite the 
study start-up of new clinical trials. The author concludes that the Challenge should 
continue and once more data is available, the CTSI should determine if it is feasible for 
departments to be required to adhere to the Challenge guidelines to allow for a continued 
improvement in CTA turnaround times.  
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 In conclusion, the information presented for this capstone project was intended to 
inform WFBMC of best practices from other institutions that could be implemented to 
better facilitate CTAs and to reduce the time it takes to activate a new clinical trial. This 
information along with continuing and expanding the 60-Day Challenge and the 
recommendations from senior leaders should be considered process improvements 
worthy of implementation. These recommendations will allow WFBMC to build a 
research administrative infrastructure that attracts industry sponsors and is capable of 
processing CTAs in a more timely and efficient way. This will put WFBMC in a position 
to rapidly open clinical trials to enrollment and give their patients opportunities to 
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Office of Sponsored Programs Assessment 
 
Please take a few minutes to provide feedback to the Office of Sponsored Programs 
(OSP). 
 
Your responses to this survey, which are anonymous and confidential, will be used to 
shape our actions and act as a baseline that can be used for future assessments. 
 
Please consider only your experiences in the last 12 months when answering the survey. 
Please skip or select "Not Applicable" for any questions that do not apply. 
 
The survey should take about 10 minutes and covers the following topics: 
Proposal Review and Submission InfoEd 
Contract Negotiation  
Subaward Negotiation  
Account Setup 
Award Management  
















How long have you been doing/involved in 0-1 years 
    research/sponsored activity at WFUHS? 2-4  years  
  5-10 years 
  11-20 years 
  greater than 20 years 
 
How long have you been doing/involved in 0-1 years 
   research/sponsored activity anywhere? 2-4  years  
  5-10 years 
  11-20 year 
  greater than 20 years 
 
Please describe your role in the 
research/sponsored activity community. What is  
your role?   
 Faculty 
 Staff 
 Central Office 
 
 
What category best describes the focus of your Basic/Animal  Science  
research? Check all that apply. Clinical/Population Science   
 Not Applicable 
 
Which of the following research/sponsored Preaward 
activities are you involved in? Check all that  Postaward  
 apply. Contracts 
 
 
Proposal Review and Submission 
(Please consider only activity in the last 12 months in your responses.) 
Indicate how effective OSP is at facilitating the Very Effective 
overall proposal review, approval, and  Effective 
submission process. Somewhat Effective 
 Ineffective  
 Very Ineffective 
 Not Applicable 
 
In terms of minimizing the investigators  Significantly Above Expectations  
Administrative burden, how well does the  Above Expectations 
WFUHS overall proposal review, approval,  Meets Expectations         
and submission process meet expectations? Below Expectations 
 Significantly Below Expectations  




Please rate your overall satisfaction with the  Very Satisfied  
changes which have been made to the   Satisfied 
proposal review, approval, and submission   Neither Satisfied nor Dissatisfied 
process.  Dissatisfied  
  Very Dissatisfied 
  Not aware changes had been made. 
  Not Applicable 
 
InfoEd 
(Please consider only activity in the last 12 months in your responses.) 
 
What is your overall satisfaction with the  Very Satisfied 
product InfoEd? Satisfied 
 Neither Satisfied nor Dissatisfied 
 Dissatisfied 
 Very Dissatisfied  
 Not Applicable 
 
What is your level of proficiency with the  Beginner  
system? Intermediate  
 Regular User 
 Intermediate Seasonal User  
 Expert 
 Not Applicable 
 
Contract Negotiation (Industry)  
(Please consider only activity in the last 12 months in your responses.) 
 
Indicate how effective OSP is at finalizing   Very Effective 
Industry research contracts in terms of   Effective 
speed/timeliness of execution (not including   Somewhat Effective  
outgoing subcontracts).             Ineffective 
       Very Ineffective  
       Not Applicable 
 
 
Indicate how effective OSP is at communicating  Very Effective 
the status of industry contract negotiations.  Effective 
       Somewhat Effective  
       Ineffective 
       Very Ineffective  





(Please consider only activity in the last 12 months in your responses.) 
 
In your estimation, how long does it take OSP   0-10 days 
to issue an outgoing agreement to a    11-20 days 
Subcontractor following receipt of the primary   21-30 days  
award to WFUHS?     30-60 days 
       More than 60 days  
       I don't know 
       Not Applicable 
 
Indicate how effective OSP is at facilitating the  Very Effective 
outgoing subcontracting process.   Effective 
       Somewhat Effective  
       Ineffective 
       Very Ineffective  
       I don't know 
       Not Applicable 
 
In the last year, we have added the option to be  Very Satisfied 
trained and use the Subaward Tool to initiate  Satisfied 
subawards at the department level. Please rate  Neither Satisfied nor Dissatisfied       
your overall satisfaction with the changes which  Dissatisfied 
have been made to the outgoing subcontract   Very Dissatisfied 
process.       Not aware changes had been made.  
       Not Applicable 
 
Have you used the Subaward Tool to initiate an  Yes 
agreement?      No 
 
Has your department used the Subaward Tool  Yes 
to initiate an agreement?    No 
       I don't know 
 
Do you believe the tool streamlines the   Yes 
outgoing subcontract process?    No 
 
Are you/your department interested in using    Yes  
The Tool?      No 
Account Setup 
(Please consider only activity in the last 12 months in your responses.) 
In your estimation, how long does it take for a   0-5 days 
fully executed award (externally funded) to be   6-10 days 
set up in the financial system (i.e. from the   11-15 days 
day the award arrives in OSP until the    15-20 days 
chartfield is ready for spending to occur)?  More than 20 days 
       I don't know  
       Not Applicable 
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Indicate how effective OSP is at facilitating the  Very Effective 
chartfield setup process for externally    Effective 
sponsored projects.     Somewhat Effective 
       Ineffective 
       Very Ineffective  
       I don't know 
       Not Applicable 
 
In September 2016, we dedicated a person   Very Satisfied                
to the setup process. Please rate your overall   Satisfied 
satisfaction to the changes which have been   Neither Satisfied nor Dissatisfied  
made to the award setup process.   Dissatisfied 
       Very Dissatisfied 
       Not aware changes had been made.  
       Not Applicable 
 
Award Management 
(Please consider only activity in the last 12 months in your responses.) 
 
I have the tools that I need to understand the  Strongly Agree 
current financial state of my projects (for   Agree 
example access to fund balance report,   Neither Agree nor Disagree 
monthly detailed statements, salary reports).  Disagree 
       Strongly Disagree  
       Not Applicable 
 
What types of information are you missing? 
 
 
I have received adequate support from my   Strongly Agree  
Department administrator necessary to    Agree 
conduct my research/sponsored activity   Neither Agree nor Disagree 
effectively and efficiently.    Disagree 
       Strongly Disagree  





(Please consider only activity in the last 12 months in your responses.) 
 
I believe it would be most accurate if I reported  Monthly 
My effort: Quarterly    
 Bi-annually  
 Annually    
 Not Applicable 
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How user-friendly is the WFUHS effort reporting  Very User-Friendly 
system?      Moderately User-Friendly 
       Somewhat User-Friendly  
       Not User-Friendly 
       Not At All User-Friendly  
       Not Applicable 
 
How user-friendly is the WFUHS effort reporting  Very User-Friendly 
process?      User-Friendly 
       Somewhat User-Friendly  
       Not User-Friendly 
       Not At All User-Friendly  
       Not Applicable 
 
Award Closeout 
(Please consider only activity in the last 12 months in your responses.) 
OSP has a clear and consistent process for  Strongly Agree 
closing externally sponsored awards. Agree 
 Neither Agree nor Disagree  
 Disagree   
 Strongly Disagree  
 Not Applicable 
 
In my opinion, OSP is very diligent in ensuring  Strongly Agree 
the final financial reports/invoices are submitted  Agree 
in a timely fashion. Neither Agree nor Disagree 
 Disagree 
 Strongly Disagree  
 Not Applicable 
 
In the last year, we have been notifying   Very Satisfied 
Departments of upcoming NIH end dates and   Satisfied 
final report due dates. We have also dedicated   Neither Satisfied nor Dissatisfied 
a resource focusing on industry closeouts.   Dissatisfied 
Please rate your overall satisfaction with the   Very Dissatisfied 
changes made to the award closeout process.  I was not aware changes had been 
made.       Not Applicable 
 
 
Please answer the following questions regarding your experience with 
the Preaward Office in the past 12 months. 
 
The individuals within the OSP Preaward Office  Strongly Agree  
have the right level of expertise and knowledge  Agree 
To perform their job duties and answer my   Neither Agree nor Disagree 
questions.      Disagree 
       Strongly Disagree  




The OSP Preaward Office team members   Strongly Agree  
display a strong customer service   Agree 
attitude to my email and/or phone   Neither Agree nor Disagree 
inquiries.      Disagree 
       Strongly Disagree  
       Not Applicable 
 
Please rate your overall satisfaction with the  Very Satisfied 
response time of the OSP Preaward Office to   Satisfied 
your questions, emails and/or phone inquiries.  Neither Satisfied nor Dissatisfied  
       Dissatisfied 
       Very Dissatisfied  
       Not Applicable 
 
Please answer the following questions regarding your experience with the 
Postaward Office in the past 12 months. 
 
The individuals within the OSP Postaward  Strongly Agree  
Office have the right level of expertise and  Agree 
knowledge to perform their job duties and  Neither Agree nor Disagree 
answer my questions. Disagree 
 Strongly Disagree  
 Not Applicable 
 
The OSP Postaward Office team members   Strongly Agree 
display a strong customer service attitude to  Agree 
my email and/or phone inquiries. Neither Agree nor Disagree 
 Disagree 
 Strongly Disagree  
 Not Applicable 
 
Please rate your overall satisfaction with the Very Satisfied 
response time of the OSP Postaward Office.  Satisfied 
     s.  Neither Satisfied nor Dissatisfied 
  Dissatisfied 
  Very Dissatisfied  
   Not Applicable 
 
Please answer the following questions regarding your experience with 
the Contracts Office in the past 12 months. 
 
The individuals within the OSP Contracts  Strongly Agree Office    
Have the right level of expertise and knowledge           Agree          
to perform their job duties and answer my   Neither Agree nor Disagree 
questions.  Disagree 
  Strongly Disagree  





The OSP Contracts Office team members display  Strongly Agree 
a strong customer service attitude to my email  Agree 
and/or phone inquiries.     Neither Agree nor Disagree 
       Disagree 
       Strongly Disagree  
       Not Applicable 
 
Please rate your overall satisfaction with the  Very Satisfied 
response time of the OSP Contracts Office to   Satisfied 
your questions, emails and/or phone inquiries.  Neither Satisfied nor Dissatisfied  
       Dissatisfied 
       Very Dissatisfied  
       Not Applicable 
           
 General Questions 
 
Would you prefer to be copied on all email Yes 
correspondence, rather than just your No  
departmental administrator? 
 
Are you aware of the following OSP training Research Administration Certificate 
program opportunities? Please select all that RA Sessions 
you are familiar with. Periodic Webinars 
 InfoEd Training  
 Subaward Tool Training 
 
How effective were the OSP trainings that you Very Effective 
attended? Effective 
 Somewhat Effective  
 Ineffective 
 Very Ineffective 
 Not Applicable 
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